AR064154A1 - Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas - Google Patents

Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas

Info

Publication number
AR064154A1
AR064154A1 ARP070105448A ARP070105448A AR064154A1 AR 064154 A1 AR064154 A1 AR 064154A1 AR P070105448 A ARP070105448 A AR P070105448A AR P070105448 A ARP070105448 A AR P070105448A AR 064154 A1 AR064154 A1 AR 064154A1
Authority
AR
Argentina
Prior art keywords
cr14r15
nr10r11
alkyl
nr12c
optionally substituted
Prior art date
Application number
ARP070105448A
Other languages
English (en)
Spanish (es)
Original Assignee
Piramed Ltd
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39403189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064154(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Piramed Ltd, Genentech Inc filed Critical Piramed Ltd
Publication of AR064154A1 publication Critical patent/AR064154A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ARP070105448A 2006-12-07 2007-12-05 Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas AR064154A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87342206P 2006-12-07 2006-12-07

Publications (1)

Publication Number Publication Date
AR064154A1 true AR064154A1 (es) 2009-03-18

Family

ID=39403189

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105448A AR064154A1 (es) 2006-12-07 2007-12-05 Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas

Country Status (19)

Country Link
US (1) US9487533B2 (enExample)
EP (1) EP2114950B1 (enExample)
JP (1) JP5500990B2 (enExample)
KR (1) KR101507182B1 (enExample)
CN (1) CN101675053B (enExample)
AR (1) AR064154A1 (enExample)
AU (1) AU2007333243B2 (enExample)
BR (1) BRPI0717907A2 (enExample)
CA (1) CA2671845C (enExample)
CL (1) CL2007003523A1 (enExample)
ES (1) ES2571028T3 (enExample)
IL (1) IL199151A (enExample)
MX (1) MX2009005925A (enExample)
NO (1) NO342697B1 (enExample)
PE (1) PE20081353A1 (enExample)
RU (1) RU2470936C2 (enExample)
TW (1) TW200829594A (enExample)
WO (1) WO2008073785A2 (enExample)
ZA (1) ZA200904531B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1953417B (zh) * 1996-09-04 2010-12-29 英特托拉斯技术公司 一种从用户站点向外部站点发布使用数据的方法
US7888352B2 (en) 2006-12-07 2011-02-15 Piramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use
US7893060B2 (en) * 2007-06-12 2011-02-22 F. Hoffmann-La Roche Ag Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
US8247397B2 (en) * 2007-09-12 2012-08-21 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042607A1 (en) * 2007-09-24 2009-04-02 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
WO2009085230A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
WO2010014939A1 (en) * 2008-07-31 2010-02-04 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
EP2341052A4 (en) * 2008-09-05 2011-10-12 Shionogi & Co RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
AU2009304596A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1P receptors modulators
AU2009304598B2 (en) 2008-10-17 2015-01-29 Akaal Pharma Pty Ltd S1P receptors modulators and their use thereof
RS54230B1 (sr) * 2009-01-08 2015-12-31 Curis Inc. Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CA2753285A1 (en) * 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
CA2987743A1 (en) * 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Purine derivatives and their use as immunosuppressive agents
WO2010110782A1 (en) 2009-03-24 2010-09-30 Sumitomo Chemical Company, Limited Method for manufacturing a boronic acid ester compound
JP5781066B2 (ja) 2009-05-27 2015-09-16 ジェネンテック， インコーポレイテッド ｐ１１０δに対して選択的な二環式ピリミジンＰＩ３Ｋ阻害剤化合物及び使用方法
CA2772371A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CN102480961A (zh) * 2009-06-24 2012-05-30 健泰科生物技术公司 与含氧杂环稠合的嘧啶化合物、组合物和使用方法
JP5546636B2 (ja) 2009-09-28 2014-07-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾキセピンｐｉ３ｋ阻害剤化合物及び使用方法
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
AU2010316780B2 (en) 2009-11-05 2015-07-16 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
US8828990B2 (en) * 2009-11-12 2014-09-09 Genentech, Inc. N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
JP5579864B2 (ja) * 2009-11-12 2014-08-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｎ−９−置換プリン化合物、組成物及び使用の方法
CN102762565A (zh) 2010-02-22 2012-10-31 弗·哈夫曼-拉罗切有限公司 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
RU2585177C2 (ru) * 2010-06-23 2016-05-27 Ханми Сайенс Ко., Лтд. Новые конденсированные пиримидиновые производные для ингибирования тирозинкиназной активности
US8293736B2 (en) 2010-07-14 2012-10-23 F. Hoffmann La Roche Ag Purine compounds selective for PI3K P110 delta, and methods of use
DE102010049595A1 (de) * 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
DK2651951T3 (en) 2010-12-16 2014-12-08 Hoffmann La Roche TRICYCLIC PI3K INHIBITOR COMPOUNDS AND PROCEDURES FOR USE THEREOF
US20140206678A1 (en) * 2011-01-27 2014-07-24 Kadmon Corporation, Llc Inhibitors of mtor kinase as anti -viral agent
MX2013008822A (es) 2011-02-09 2013-10-07 Hoffmann La Roche Compuestos heterociclicos como inhibidores de cinasa fosfatidilinositol-3 (pi3).
EP2683243A4 (en) * 2011-03-09 2014-12-03 Celgene Avilomics Res Inc PI3 KINASE INHIBITORS AND USES THEREOF
EP2688891B1 (en) 2011-03-21 2017-11-15 F. Hoffmann-La Roche AG Benzoxazepin compounds selective for pi3k p110 delta and methods of use
ME02451B (me) 2011-04-01 2016-09-20 Curis Inc Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink
PH12013502033A1 (en) 2011-04-08 2014-01-06 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
KR101992311B1 (ko) 2011-05-04 2019-09-27 리젠 파마슈티컬스 소시에떼 아노님 단백질 키나아제의 조절제로서 신규한 화합물
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
EA033830B1 (ru) 2011-11-09 2019-11-29 Janssen Sciences Ireland Uc Производные аденина в качестве активаторов толл-подобных рецепторов tlr7
WO2013078126A1 (en) 2011-11-23 2013-05-30 Cancer Research Technology Limited Thienopyrimidine inhibitors of atypical protein kinase c
JP6077642B2 (ja) 2012-04-10 2017-02-08 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用
KR20160027218A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
EP2858666B1 (en) 2012-06-08 2019-09-04 F.Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CA2876995C (en) 2012-07-04 2020-10-06 Rhizen Pharmaceuticals Sa Novel selective pi3k delta inhibitors
JP6250046B2 (ja) 2012-07-13 2017-12-20 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症の処置のための大環状プリン
ES2594078T3 (es) * 2012-10-10 2016-12-15 F. Hoffmann-La Roche Ag Proceso para preparar compuestos de tienopirimidina
MX365114B (es) 2012-10-10 2019-05-23 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades.
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
MX361585B (es) 2012-11-16 2018-12-11 Janssen Sciences Ireland Uc Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas.
KR102300861B1 (ko) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
CN105338983B (zh) 2013-03-29 2019-10-25 爱尔兰詹森科学公司 用于治疗病毒感染的大环脱氮-嘌呤酮
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
MY191923A (en) 2013-05-24 2022-07-18 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
US10385054B2 (en) 2013-06-27 2019-08-20 Janssen Sciences Ireland Unlimited Company Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
KR102322425B1 (ko) * 2013-07-30 2021-11-05 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체
JP6441910B2 (ja) * 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR102343802B1 (ko) * 2014-06-09 2021-12-28 수미토모 케미칼 컴퍼니 리미티드 피리딘 화합물의 제조 방법
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
KR20160082062A (ko) 2014-12-30 2016-07-08 한미약품 주식회사 싸이옥소 퓨로피리미디논 유도체의 제조방법 및 이에 사용되는 중간체
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
CN107635560A (zh) 2015-06-29 2018-01-26 豪夫迈·罗氏有限公司 用他塞利昔布进行治疗的方法
CN106467545B (zh) * 2015-08-20 2018-10-16 北大方正集团有限公司 一种噻吩并嘧啶化合物
JP7114076B2 (ja) * 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
JP6742452B2 (ja) * 2016-06-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｂｖ感染の処置および予防のための新規のテトラヒドロピリドピリミジン
WO2018002319A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Uc Dihydropyranopyrimidines for the treatment of viral infections
EP3519406B1 (en) 2016-09-29 2022-02-23 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
JP7078960B2 (ja) 2017-01-26 2022-06-01 エス． トサントリゾス，ヨウラ 置換二環式ピリミジン系化合物および組成物ならびにその使用
CN107163061A (zh) * 2017-04-14 2017-09-15 江西科技师范大学 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
EP4331679A3 (en) 2017-06-21 2024-04-03 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
MX2021002742A (es) 2018-09-11 2021-08-11 Curis Inc Terapia combinada con un inhibidor de la fosfoinositida 3-quinasa con un resto de unión a zinc.
CN109540859B (zh) * 2018-11-27 2021-02-09 上海交通大学 一种水体中抗生素的分析和含量预测方法
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3911649A1 (en) 2019-01-17 2021-11-24 F. Hoffmann-La Roche AG A process for the preparation of tetrahydropyridopyrimidines
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
EP4161519A4 (en) * 2020-06-03 2024-07-17 Yumanity Therapeutics, Inc. PURINES AND METHODS OF USE
WO2022152229A1 (zh) * 2021-01-15 2022-07-21 深圳微芯生物科技股份有限公司 一类吗啉衍生物及其制备方法和应用
CN115991716B (zh) * 2021-10-19 2025-10-17 中国药科大学 嘧啶并环类化合物及其衍生物、制备方法、药物组合物和应用
CN116262758B (zh) * 2021-12-15 2025-02-28 上海博悦生物科技有限公司 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途
CN114539293B (zh) * 2022-02-24 2023-09-22 广东晨康生物科技有限公司 一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
DE1959403A1 (de) 1969-11-26 1971-06-03 Thomae Gmbh Dr K Neue 2-(5-Nitro-2-furyl)-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2050814A1 (de) * 1970-10-16 1972-04-20 Dr. Karl Thomae Gmbh, 7950 Biberach Neue Verfahren zur Herstellung von 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidinen
BE759493A (fr) 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
DE2058085A1 (de) * 1970-11-26 1972-05-31 Thomae Gmbh Dr K Neues Verfahren zur Herstellung von 4-Morpholino-thieno[3,2-d]pyrimidinen
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
CH592668A5 (enExample) 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
RU1391052C (ru) * 1986-08-25 1993-11-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 5-формилтиено [2,3-D]пиримидина, обладающие противогерпетической активностью
US5075305A (en) 1991-03-18 1991-12-24 Warner-Lambert Company Compound, composition and use
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JPWO2002026745A1 (ja) * 2000-09-29 2004-02-05 日本曹達株式会社 チエノピリミジン化合物とその塩並びに製造方法
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
CN1960809B (zh) * 2004-06-03 2010-10-13 诺信公司 一种粉末涂料系统
US7557112B2 (en) 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
ES2347187T3 (es) 2006-04-26 2010-10-26 F. Hoffmann-La Roche Ag Derivado de tieno(3,2-d)pirimidina, util como un inhibidor de pi3k.
AU2007242594A1 (en) 2006-04-26 2007-11-01 F. Hoffmann-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
BRPI0710943A2 (pt) 2006-04-26 2012-06-26 Genentech Inc compostos farmacêuticos
CA2650295C (en) 2006-04-26 2015-12-29 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
US7888352B2 (en) 2006-12-07 2011-02-15 Piramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use

Also Published As

Publication number Publication date
US9487533B2 (en) 2016-11-08
PE20081353A1 (es) 2008-11-12
NO342697B1 (no) 2018-07-09
ES2571028T3 (es) 2016-05-23
US20080269210A1 (en) 2008-10-30
WO2008073785A2 (en) 2008-06-19
RU2470936C2 (ru) 2012-12-27
ZA200904531B (en) 2010-09-29
CA2671845A1 (en) 2008-06-19
TW200829594A (en) 2008-07-16
KR20090106508A (ko) 2009-10-09
JP2010512337A (ja) 2010-04-22
CN101675053A (zh) 2010-03-17
KR101507182B1 (ko) 2015-03-30
IL199151A0 (en) 2010-03-28
CA2671845C (en) 2015-03-24
JP5500990B2 (ja) 2014-05-21
CL2007003523A1 (es) 2008-08-22
EP2114950A2 (en) 2009-11-11
WO2008073785A3 (en) 2008-08-28
NO20092565L (no) 2009-09-07
IL199151A (en) 2017-01-31
AU2007333243A1 (en) 2008-06-19
CN101675053B (zh) 2014-03-12
BRPI0717907A2 (pt) 2013-11-05
EP2114950B1 (en) 2016-03-09
MX2009005925A (es) 2009-08-12
RU2009125916A (ru) 2011-01-20
AU2007333243B2 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
AR064154A1 (es) Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas
AR064155A1 (es) Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
AR068402A1 (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
HRP20192336T1 (hr) Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita
AR060632A1 (es) Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso
JP2016530262A5 (enExample)
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
AR076984A1 (es) Derivados de pirazol oxadiazol
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
AR077507A1 (es) Derivados de naftiridina-1-ona y composiciones farmaceuticas que los comprenden como inhibidores de cinasa syk
ES2855732T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP
AR067093A1 (es) N-(2-(hetaril) arilsulfonamidas y n-(2-( heteraril) hetaril) arilsulfonamidas
AR078187A1 (es) Derivados heterociclicos de benzoxazepina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer.
CO6140024A2 (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer
AR079199A1 (es) Composiciones farmaceuticas que comprenden ligandos de receptores sigma
RU2018112252A (ru) Конденсированное пиримидиновое соединение или его соль
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.
AR085637A1 (es) Derivados de pirido[2,3-b]pirazina
JP2019521097A5 (enExample)
AR076187A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos y composicion farmaceutica que los contienen
JP2016528245A5 (enExample)
RU2017110211A (ru) ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ
RU2015140387A (ru) Пиридопиримидиновое или пиримидопиримидиновое соединение, способ получения, фармацевтическая композиция и применение указанных соединений
JP2017529365A5 (enExample)

Legal Events

Date Code Title Description
FB Suspension of granting procedure